◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › X › XENE

Xenon Pharmaceuticals Inc (XENE) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-15

Xenon Pharmaceuticals Inc (XENE) operates in the BIOTECHNOLOGY industry and is headquartered in Burnaby, Canada with about 358 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, XENE reported $8M in revenue and ($346M) in net income.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.

Interactive charts & full statements →

XENE Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	—	$8M	$0M	$0M	$9M	$18M	$32M	$7M	$0M	$0M	$2M	$16M	$28M	$27M	$14M	$7M
Gross Profit	—	$5M	($3M)	($168M)	$9M	$18M	$32M	$7M	($6M)	($25M)	$1M	$16M	$22M	$21M	$7M	$7M
Gross Margin %	—	66.1%	—	—	100.0%	100.0%	100.0%	100.0%	—	-8122.8%	38.2%	100.0%	79.2%	77.3%	48.8%	100.0%
Operating Income (EBIT)	($442M)	($373M)	($279M)	($214M)	($129M)	($79M)	($31M)	($43M)	($38M)	($33M)	($25M)	($9M)	$11M	$10M	($3M)	($12M)
Operating Margin %	—	-4974.3%	—	—	-1368.9%	-428.5%	-97.3%	-627.0%	—	-10474.3%	-1376.4%	-60.1%	39.1%	35.5%	-22.0%	-175.1%
Net Income	($409M)	($346M)	($234M)	($182M)	($125M)	($79M)	($29M)	($42M)	($34M)	($31M)	($23M)	($16M)	$13M	$12M	($4M)	($12M)
Net Margin %	—	-4612.1%	—	—	-1329.0%	-427.9%	-89.6%	-609.1%	—	-9872.7%	-1275.5%	-101.1%	45.9%	44.0%	-30.1%	-173.3%
EBITDA	($417M)	($342M)	($236M)	($211M)	($128M)	($78M)	($31M)	($40M)	($33M)	($30M)	($24M)	($8M)	$12M	$10M	($3M)	($11M)
Earnings Per Share (EPS)	$-4.76	$-4.36	$-3.01	$-2.73	$-2.07	$-1.81	$-0.83	$-1.60	$-1.78	$-1.71	$-1.48	$-1.10	$0.94	$1.22	$-3.23	$-9.02
Shares Outstanding (M)	100M	79M	78M	67M	61M	44M	35M	26M	19M	18M	15M	14M	14M	—	1M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XENE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	—	$0M	$0M	$0M	$0M	$8M	$3M	$0M
Gross Profit	—	($1M)	($1M)	($77M)	($1M)	$8M	$1M	($1M)
Gross Margin %	—	—	—	—	—	100.0%	50.0%	—
Operating Income (EBIT)	($123M)	($112M)	($110M)	($96M)	($94M)	($73M)	($77M)	($74M)
Operating Margin %	—	—	—	—	—	-969.8%	-3079.4%	—
Net Income	($111M)	($102M)	($105M)	($91M)	($85M)	($65M)	($66M)	($63M)
Net Margin %	—	—	—	—	—	-867.3%	-2610.7%	—
EBITDA	($111M)	($112M)	($104M)	($90M)	($94M)	($72M)	($77M)	($73M)
Earnings Per Share (EPS)	$-1.11	$-1.17	$-1.33	$-1.15	$-1.07	$-0.83	$-0.84	$-0.81
Shares Outstanding (M)	100M	87M	79M	79M	79M	79M	78M	78M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XENE Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($338M)	($279M)	($181M)	($145M)	($98M)	($70M)	($48M)	($5M)	($35M)	($29M)	($20M)	($18M)	$0M	($3M)	$46M	($14M)
Capital Expenditures (CapEx)	$1M	$1M	$3M	$6M	$3M	$2M	$3M	$1M	$1M	$0M	$0M	$1M	$2M	$0M	$1M	$0M
Free Cash Flow (FCF)	($339M)	($280M)	($184M)	($151M)	($101M)	($72M)	($51M)	($6M)	($35M)	($29M)	($20M)	($19M)	($1M)	($3M)	$45M	($14M)
FCF Margin %	—	-3732.2%	—	—	-1074.0%	-388.1%	-157.8%	-86.0%	—	-9337.9%	-1100.7%	-119.8%	-4.5%	-12.7%	314.8%	-202.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XENE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($95M)	($89M)	($81M)	($72M)	($64M)	($62M)	($54M)	($50M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$1M
Free Cash Flow (FCF)	($96M)	($89M)	($82M)	($72M)	($64M)	($62M)	($55M)	($50M)
FCF Margin %	—	—	—	—	—	-822.6%	-2192.7%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XENE Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Assets	$1.3B	$982M	$798M	$965M	$754M	$572M	$189M	$148M	$122M	$46M	$67M	$64M	$87M	$54M	$63M
Cash & Cash Equivalents	$120M	$199M	$143M	$149M	$57M	$176M	$45M	$25M	$68M	$20M	$17M	$59M	$72M	$38M	$60M
Total Liabilities	$53M	$400M	$43M	$37M	$33M	$22M	$18M	$56M	$19M	$10M	$4M	$3M	$15M	$30M	$51M
Total Debt (Short + Long-Term)	$1M	$2M	$1M	$1M	$0M	$1M	$0M	$16M	$30M	$7M	$0M	$0M	$0M	$0M	$2M
Total Shareholders' Equity	$1.2B	$582M	$755M	$928M	$721M	$550M	$171M	$92M	$103M	$36M	$64M	$61M	$73M	$24M	$13M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive XENE viewer.

Other Companies in BIOTECHNOLOGY

TLX · Telix Pharmaceuticals Limited — $4 billion
RLAY · Relay Therapeutics Inc — $4 billion
ABCL · Abcellera Biologics Inc — $4 billion
CELC · Celcuity LLC — $4 billion
IDYA · Ideaya Biosciences Inc — $4 billion
TNGX · Tango Therapeutics Inc — $4 billion
TARS · Tarsus Pharmaceuticals Inc — $4 billion
ELVN · Enliven Therapeutics Inc. — $4 billion

← XEMU All “X” companies XEOD →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.